ES2421587T3 - Uso de derivados de pirimidilaminobenzamida para el tratamiento de mastocitosis sistémica - Google Patents
Uso de derivados de pirimidilaminobenzamida para el tratamiento de mastocitosis sistémicaInfo
- Publication number
- ES2421587T3 ES2421587T3 ES06751956T ES06751956T ES2421587T3 ES 2421587 T3 ES2421587 T3 ES 2421587T3 ES 06751956 T ES06751956 T ES 06751956T ES 06751956 T ES06751956 T ES 06751956T ES 2421587 T3 ES2421587 T3 ES 2421587T3
- Authority
- ES
- Spain
- Prior art keywords
- treatment
- systemic mastocytosis
- pyrimidylaminobenzamide derivatives
- methyl
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Uso de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-N-[5-(4-metil-1H-imidazol-1-il)-3-(trifluorometil)fenil]-benzamida de fórmula (ll):**Fórmula** o un N-óxido o sales farmacéuticamente aceptables del mismo, para la fabricación de un medicamento para el tratamiento o la prevención de mastocitosis sistémicaagresiva, en el que dicha mastocitosis sistémica agresiva tiene resistencia al tratamiento de imatinib.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67674005P | 2005-05-02 | 2005-05-02 | |
PCT/US2006/016541 WO2006119154A1 (en) | 2005-05-02 | 2006-05-01 | Use of pyrimidylamimobenzamide derivatives for the treatment of systematic mastocytosis |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2421587T3 true ES2421587T3 (es) | 2013-09-04 |
Family
ID=36867557
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES06751956T Active ES2421587T3 (es) | 2005-05-02 | 2006-05-01 | Uso de derivados de pirimidilaminobenzamida para el tratamiento de mastocitosis sistémica |
Country Status (14)
Country | Link |
---|---|
US (2) | US20080176879A1 (es) |
EP (1) | EP1879585B1 (es) |
JP (1) | JP5129123B2 (es) |
KR (1) | KR101376875B1 (es) |
CN (2) | CN103638028A (es) |
AU (1) | AU2006242311B2 (es) |
BR (1) | BRPI0609296A2 (es) |
CA (1) | CA2606716C (es) |
ES (1) | ES2421587T3 (es) |
MX (1) | MX2007013741A (es) |
PL (1) | PL1879585T3 (es) |
PT (1) | PT1879585E (es) |
RU (1) | RU2445960C2 (es) |
WO (1) | WO2006119154A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1882344A (zh) | 2003-11-18 | 2006-12-20 | 诺瓦提斯公司 | Kit突变形式的抑制剂 |
CA2689989A1 (en) | 2007-06-04 | 2008-12-11 | Avila Therapeutics, Inc. | Heterocyclic compounds and uses thereof |
JO3634B1 (ar) * | 2009-11-17 | 2020-08-27 | Novartis Ag | طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r |
WO2016104474A1 (ja) | 2014-12-26 | 2016-06-30 | 花王株式会社 | 環状ジケトン化合物の製造方法 |
WO2018050801A1 (en) * | 2016-09-16 | 2018-03-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of systemic mastocytosis |
AU2019285066B2 (en) | 2018-06-15 | 2024-06-13 | Handa Pharmaceuticals, Inc. | Kinase inhibitor salts and compositions thereof |
KR102535842B1 (ko) | 2020-07-31 | 2023-05-23 | (주)파로스아이바이오 | 2,3,5-치환된 싸이오펜 화합물의 비만세포증 예방, 개선 또는 치료 용도 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW225528B (es) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
US5521184A (en) * | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
US5543520A (en) * | 1993-10-01 | 1996-08-06 | Ciba-Geigy Corporation | Pyrimidine derivatives |
AU693475B2 (en) | 1993-10-01 | 1998-07-02 | Novartis Ag | Pyrimidineamine derivatives and processes for the preparation thereof |
BR9407799A (pt) * | 1993-10-12 | 1997-05-06 | Du Pont Merck Pharma | Composição de matéria método de tratamento e composição farmaceutica |
GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
WO1998055152A1 (en) | 1997-06-06 | 1998-12-10 | Baylor College Of Medicine | The mast cell secretory machine as a target for anti-allergy drug development |
CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
JP2002516820A (ja) | 1997-11-13 | 2002-06-11 | ヒスタテク・エルエルシー | 低分子量ペプチド及び喘息及び炎症の治療方法 |
US20040157855A1 (en) | 2001-04-05 | 2004-08-12 | Michael Heinrich | Use of n-phenyl-2-pyrimidineamine derivativea against mast cell-based diseases like allergic disorders |
GB0108606D0 (en) * | 2001-04-05 | 2001-05-23 | Novartis Ag | Organic compounds |
CA2452171A1 (en) * | 2001-06-29 | 2003-01-09 | Ab Science | Use of potent, selective and non toxic c-kit inhibitors for treating mastocytosis |
TWI315982B (en) | 2001-07-19 | 2009-10-21 | Novartis Ag | Combinations comprising epothilones and pharmaceutical uses thereof |
US20050095237A1 (en) * | 2001-12-11 | 2005-05-05 | Emtage Peter C. | Methods of therapy and diagnosis using targeting of cells that express P2Y10 |
CA2478640A1 (en) | 2002-03-13 | 2003-09-18 | F. Hoffmann-La Roche Ag | Method for selecting drug sensitivity-determining factors and method for predicting drug sensitivity using the selected factors |
JP2005508846A (ja) * | 2002-04-05 | 2005-04-07 | ノバルティス アクチエンゲゼルシャフト | アレルギー性疾患のような肥満細胞系疾患に対するn−フェニル−2−ピリミジンアミン誘導体の使用 |
JP4032140B2 (ja) * | 2002-07-02 | 2008-01-16 | 大原商事株式會社 | つけ爪の取り付け方法 |
GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
GB0223341D0 (en) | 2002-10-08 | 2002-11-13 | Groningen Acad Ziekenhuis | Organic compounds |
TWI324604B (en) | 2003-06-18 | 2010-05-11 | Novartis Ag | New use of staurosporine derivatives |
US20080096864A1 (en) | 2003-09-19 | 2008-04-24 | Sasa Dimitrijevic | Treatment Of Gastrointestinal Stromal Tumors With Imatinib And Midostaurin |
CN1882344A (zh) | 2003-11-18 | 2006-12-20 | 诺瓦提斯公司 | Kit突变形式的抑制剂 |
-
2006
- 2006-05-01 WO PCT/US2006/016541 patent/WO2006119154A1/en active Application Filing
- 2006-05-01 AU AU2006242311A patent/AU2006242311B2/en not_active Ceased
- 2006-05-01 MX MX2007013741A patent/MX2007013741A/es active IP Right Grant
- 2006-05-01 PL PL06751956T patent/PL1879585T3/pl unknown
- 2006-05-01 JP JP2008510093A patent/JP5129123B2/ja not_active Expired - Fee Related
- 2006-05-01 KR KR1020077025364A patent/KR101376875B1/ko not_active IP Right Cessation
- 2006-05-01 US US11/911,575 patent/US20080176879A1/en not_active Abandoned
- 2006-05-01 PT PT67519561T patent/PT1879585E/pt unknown
- 2006-05-01 CN CN201310652355.4A patent/CN103638028A/zh active Pending
- 2006-05-01 BR BRPI0609296-9A patent/BRPI0609296A2/pt not_active IP Right Cessation
- 2006-05-01 RU RU2007144530/04A patent/RU2445960C2/ru not_active IP Right Cessation
- 2006-05-01 ES ES06751956T patent/ES2421587T3/es active Active
- 2006-05-01 CA CA2606716A patent/CA2606716C/en not_active Expired - Fee Related
- 2006-05-01 CN CNA2006800149433A patent/CN101171013A/zh active Pending
- 2006-05-01 EP EP06751956.1A patent/EP1879585B1/en not_active Not-in-force
-
2010
- 2010-04-29 US US12/769,734 patent/US8673930B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
PL1879585T3 (pl) | 2013-08-30 |
KR20080004563A (ko) | 2008-01-09 |
US20100210673A1 (en) | 2010-08-19 |
US20080176879A1 (en) | 2008-07-24 |
AU2006242311B2 (en) | 2010-03-04 |
EP1879585B1 (en) | 2013-04-17 |
CA2606716A1 (en) | 2006-11-09 |
MX2007013741A (es) | 2008-01-21 |
CN101171013A (zh) | 2008-04-30 |
JP5129123B2 (ja) | 2013-01-23 |
CN103638028A (zh) | 2014-03-19 |
RU2007144530A (ru) | 2009-06-10 |
KR101376875B1 (ko) | 2014-03-27 |
JP2008540420A (ja) | 2008-11-20 |
US8673930B2 (en) | 2014-03-18 |
AU2006242311A1 (en) | 2006-11-09 |
CA2606716C (en) | 2013-07-23 |
RU2445960C2 (ru) | 2012-03-27 |
WO2006119154A1 (en) | 2006-11-09 |
EP1879585A1 (en) | 2008-01-23 |
BRPI0609296A2 (pt) | 2010-03-23 |
PT1879585E (pt) | 2013-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2421587T3 (es) | Uso de derivados de pirimidilaminobenzamida para el tratamiento de mastocitosis sistémica | |
GEP20125691B (en) | Compounds and compositions as protein kinase inhibitors | |
UY35998A (es) | 1-(3-(tert-BUTIL)1-(p-TOLIL)-1H-PIRAZOL-5-IL)-3-(4-((2-((6-ETILPIRAZIN-2-IL)AMINO)PIRIDIN-4-IL)METOXI)NAFTALEN-1-IL) UREA Y SUS SALES DERIVADAS FARMACÉUTICAMENTE ACEPTABLES, COMO INHIBIDORES DE P38 M AP QUINASA | |
CO6450624A2 (es) | Compuestos vinil indazolilo | |
BR112013032122A2 (pt) | liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos | |
CL2007000601A1 (es) | Compuestos derivados de heterobiciclos pirazolicos, inhibidores de la actividad de proteina tiroxina quinasa; composicion farmaceutica que comprende dichos compuestos; y uso de los compuestos en el tratamiento de una enfermedad hiperproliferativa. | |
CL2013000884A1 (es) | El compuesto (r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol cristalino, modulador del factor de crecimiento de fibroblastos (fgf); composicion farmaceutica, util en el tratamiento del cancer. | |
PT1332137E (pt) | Tratamento de tumores estromais gastrintestinais | |
RS54608B1 (en) | CGRP RECEPTOR ANTAGONITY | |
NZ590839A (en) | Treatment of pulmonary arterial hypertension | |
WO2008059551A3 (en) | Process for the preparation of imatinib and intermediates thereof | |
JP2016020375A5 (es) | ||
WO2007116025A3 (en) | Use of c-src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia | |
NZ590177A (en) | Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis | |
HRP20100265T1 (hr) | Smjesa od pirimidilaminobenzamid spojeva i imatiniba za liječenje ili prevenciju proliferativnih bolesti | |
JP2012528824A5 (es) | ||
MA35636B1 (fr) | Formulation à libération immédiate de 4-méthyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-méthyl- 1h-imidazol-1-yl)-3-(trifluorométhyl)phényl]benzamide | |
NO20056188L (no) | Anvendelse av en c-Abl-, PDGF-R- eller c-kit-tyrosinkinaseinhibitor for behandling av diabetes | |
RS54666B1 (en) | A NEW PHENYLPYRIDINE DERIVATIVE AND THE MEDICINAL PRODUCT CONTAINED | |
BRPI0517083A (pt) | uso de 4-(4-metilpiperazin-1-ilmetil)-n-{4-metil-3-(4-piridin-3-il) pirimidin-2-ilamino)fenil}-benzamida para inibir o receptor c-fms de tirosina quinase | |
BRPI0818065A8 (pt) | Quimioterapêutco derivado de indazol cristalino | |
WO2006012958A3 (en) | Combination comprising a bcrp inhibitor and 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide | |
TH114424B (th) | ยาสำเร็จรูปชนิดของแข็ง | |
TH155598A (th) | ไอโซซาโซลีน (Isoxazolines) ในฐานะเป็นตัวกระทำทางการรักษา ISOXAZOLINES AS THERAPEUTIC AGENTS | |
TH114424A (th) | สารเตรียมชนิดของแข็ง |